Paper28296763
Evaluating the immunogenicity and safety of a BiondVax-developed universal influenza vaccine (Multimeric-001) either as a standalone vaccine or as a primer to H5N1 influenza vaccine: Phase IIb study protocol.
van Doorn E and 7 others. Medicine (Baltimore), 2017. Cited by 40 papers, by iCite.
Cite this record
ConductScience Library. Evaluating the immunogenicity and safety of a BiondVax-developed universal influenza vaccine (Multimeric-001) either as a standalone vaccine or as a primer to H5N1 influenza vaccine: Phase IIb study protocol. Papers, record 28296763. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28296763
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Evaluating the immunogenicity and safety of a BiondVax-developed universal influenza vaccine (Multimeric-001) either as a standalone vaccine or as a primer to H5N1 influenza vaccine: Phase IIb study protocol.
- PubMed
- Publication types
- Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial
- PubMed
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Influenza A Virus, H5N1 Subtype | Major topic |
| Influenza Vaccines | Major topic |
| Influenza, Human | Major topic |
| Adolescent | |
| Adult | |
| Cytokines | |
| Double-Blind Method | |
| Female | |
| Flow Cytometry | |
| Hemagglutination Inhibition Tests | |
| Humans | |
| Immunity, Cellular | |
| Immunity, Humoral | |
| Influenza A virus | |
| Influenza B virus | |
| Male | |
| Middle Aged | |
| Research Design | |
| Young Adult |
Source PubMed
References24
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 18704954 | Vaccine adjuvants: current challenges and future approaches. | J Pharm Sci | 2009 | https://conductscience.org/library/papers/18704954 | PubMed |
| 2 | 10480833 | How to randomise. | BMJ | 1999 | https://conductscience.org/library/papers/10480833 | PubMed |
| 3 | 25844934 | Natural T Cell-mediated Protection against Seasonal and Pandemic Influenza. Results of the Flu Watch Cohort Study. | Am J Respir Crit Care Med | 2015 | https://conductscience.org/library/papers/25844934 | PubMed |
| 4 | 22286307 | Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. | Nat Med | 2012 | https://conductscience.org/library/papers/22286307 | PubMed |
| 5 | 22318394 | Safety and immunogenicity of multimeric-001--a novel universal influenza vaccine. | J Clin Immunol | 2012 | https://conductscience.org/library/papers/22318394 | PubMed |
| 6 | 18338241 | Development of stable influenza vaccine powder formulations: challenges and possibilities. | Pharm Res | 2008 | https://conductscience.org/library/papers/18338241 | PubMed |
| 7 | 18034655 | Epitope-based vaccine against influenza. | Expert Rev Vaccines | 2007 | https://conductscience.org/library/papers/18034655 | PubMed |
| 8 | 25787138 | High-level cellular and humoral immune responses in Guinea pigs immunized intradermally with a heat-inactivated varicella-zoster virus vaccine. | Clin Vaccine Immunol | 2015 | https://conductscience.org/library/papers/25787138 | PubMed |
| 9 | 19906909 | A single-dose influenza A (H5N1) vaccine safe and immunogenic in adult and elderly patients: an approach to pandemic vaccine development. | J Virol | 2010 | https://conductscience.org/library/papers/19906909 | PubMed |
| 10 | 25455990 | Effectiveness of seasonal influenza vaccine in community-dwelling elderly people: a meta-analysis of test-negative design case-control studies. | Lancet Infect Dis | 2014 | https://conductscience.org/library/papers/25455990 | PubMed |
| 11 | 17451739 | Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. | J Immunol Methods | 2007 | https://conductscience.org/library/papers/17451739 | PubMed |
| 12 | 18374680 | Complications of viral influenza. | Am J Med | 2008 | https://conductscience.org/library/papers/18374680 | PubMed |
| 13 | 25590680 | Early estimates of seasonal influenza vaccine effectiveness - United States, January 2015. | MMWR Morb Mortal Wkly Rep | 2015 | https://conductscience.org/library/papers/25590680 | PubMed |
| 14 | 14723616 | Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. | Scand J Immunol | 2004 | https://conductscience.org/library/papers/14723616 | PubMed |
| 15 | 24241247 | Effectiveness of influenza vaccine in patients on hemodialysis--a review. | Med Sci Monit | 2013 | https://conductscience.org/library/papers/24241247 | PubMed |
| 16 | 20352064 | CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. | PLoS Med | 2010 | https://conductscience.org/library/papers/20352064 | PubMed |
| 17 | 15592819 | Detection of influenza virus: traditional approaches and development of biosensors. | Anal Bioanal Chem | 2005 | https://conductscience.org/library/papers/15592819 | PubMed |
| 18 | 29027130 | Quality Issues Identified During the Evaluation of Biosimilars by the European Medicines Agency's Committee for Medicinal Products for Human Use. | AAPS PharmSciTech | 2018 | https://conductscience.org/library/papers/29027130 | PubMed |
| 19 | 24056771 | Cellular immune correlates of protection against symptomatic pandemic influenza. | Nat Med | 2013 | https://conductscience.org/library/papers/24056771 | PubMed |
| 20 | 22658928 | Immune markers and correlates of protection for vaccine induced immune responses. | Vaccine | 2012 | https://conductscience.org/library/papers/22658928 | PubMed |
Cited by33
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 40 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39596049 | Prokaryote- and Eukaryote-Based Expression Systems: Advances in Post-Pandemic Viral Antigen Production for Vaccines. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39596049 | PubMed |
| 38362528 | Fighting flu: novel CD8+ T-cell targets are required for future influenza vaccines. | Clin Transl Immunology | 2024 | https://conductscience.org/library/papers/38362528 | PubMed |
| 38257777 | Sequential Immunizations with Influenza Neuraminidase Protein Followed by Peptide Nanoclusters Induce Heterologous Protection. | Viruses | 2024 | https://conductscience.org/library/papers/38257777 | PubMed |
| 37764217 | Nanoparticles Carrying Conserved Regions of Influenza A Hemagglutinin, Nucleoprotein, and M2 Protein Elicit a Strong Humoral and T Cell Immune Response and Protect Animals from Infection. | Molecules | 2023 | https://conductscience.org/library/papers/37764217 | PubMed |
| 37047339 | A Comparison of Etiology, Pathogenesis, Vaccinal and Antiviral Drug Development between Influenza and COVID-19. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37047339 | PubMed |
| 36820263 | Self-assembled multiepitope nanovaccine based on NoV P particles induces effective and lasting protection against H3N2 influenza virus. | Nano Res | 2023 | https://conductscience.org/library/papers/36820263 | PubMed |
| 36560509 | Flagellin-Fused Protein Targeting M2e and HA2 Induces Innate and T-Cell Responses in Mice of Different Genetic Lines. | Vaccines (Basel) | 2022 | https://conductscience.org/library/papers/36560509 | PubMed |
| 35862754 | Controlled Human Infection Models To Accelerate Vaccine Development. | Clin Microbiol Rev | 2022 | https://conductscience.org/library/papers/35862754 | PubMed |
| 35857640 | An inactivated multivalent influenza A virus vaccine is broadly protective in mice and ferrets. | Sci Transl Med | 2022 | https://conductscience.org/library/papers/35857640 | PubMed |
| 35746794 | Influenza B: Prospects for the Development of Cross-Protective Vaccines. | Viruses | 2022 | https://conductscience.org/library/papers/35746794 | PubMed |
| 35455283 | Development of a Universal Epitope-Based Influenza Vaccine and Evaluation of Its Effectiveness in Mice. | Vaccines (Basel) | 2022 | https://conductscience.org/library/papers/35455283 | PubMed |
| 35195008 | Peptides for Vaccine Development. | ACS Appl Bio Mater | 2022 | https://conductscience.org/library/papers/35195008 | PubMed |
| 35174313 | Is a universal influenza vaccine feasible? | Ther Adv Vaccines Immunother | 2019 | https://conductscience.org/library/papers/35174313 | PubMed |
| 34579269 | An Overview of Influenza Viruses and Vaccines. | Vaccines (Basel) | 2021 | https://conductscience.org/library/papers/34579269 | PubMed |
| 34073996 | Targeting Antigens for Universal Influenza Vaccine Development. | Viruses | 2021 | https://conductscience.org/library/papers/34073996 | PubMed |
| 34066605 | Quantifying the Persistence of Vaccine-Related T Cell Epitopes in Circulating Swine Influenza A Strains from 2013-2017. | Vaccines (Basel) | 2021 | https://conductscience.org/library/papers/34066605 | PubMed |
| 33987075 | In silico design of a multi-epitope peptide construct as a potential vaccine candidate for Influenza A based on neuraminidase protein. | In Silico Pharmacol | 2021 | https://conductscience.org/library/papers/33987075 | PubMed |
| 33658348 | T cell epitope screening of Epstein-Barr virus fusion protein gB. | J Virol | 2021 | https://conductscience.org/library/papers/33658348 | PubMed |
| 32957468 | Progress in the Development of Universal Influenza Vaccines. | Viruses | 2020 | https://conductscience.org/library/papers/32957468 | PubMed |
| 32788837 | Multi-Epitope Peptide-Based and Vaccinia-Based Universal Influenza Vaccine Candidates Subjected to Clinical Trials. | Malays J Med Sci | 2020 | https://conductscience.org/library/papers/32788837 | PubMed |
Genes7
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD4 | 920 | PubTator's text mining | https://conductscience.org/library/genes/920 | NCBI Gene |
| CD8A | 925 | PubTator's text mining | https://conductscience.org/library/genes/925 | NCBI Gene |
| IFNG | 3458 | PubTator's text mining | https://conductscience.org/library/genes/3458 | NCBI Gene |
| IL2 | 3558 | PubTator's text mining | https://conductscience.org/library/genes/3558 | NCBI Gene |
| IL4 | 3565 | PubTator's text mining | https://conductscience.org/library/genes/3565 | NCBI Gene |
| NEU1 | 4758 | PubTator's text mining | https://conductscience.org/library/genes/4758 | NCBI Gene |
| TNF | 7124 | PubTator's text mining | https://conductscience.org/library/genes/7124 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28296763
GET https://conductscience.org/api/papers/v1/28296763/references?page=2